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Abstract
Background: The treatment options for acute Plasmodium falciparum malaria are based on the
clinician classifying the patient as uncomplicated or severe according to the clinical and
parasitological findings. This process is not always straightforward.
Case presentation: An adult male presented to a clinic on the western border of Thailand with
a physical examination and P. falciparum trophozoite count (1.2% of infected red blood cells, IRBC)
from malaria blood smear, consistent with a diagnosis of uncomplicated P. falciparum infection.
However, the physician on duty treated the patient for severe malaria based on the reported P.
falciparum schizont count, which was very high (0.3% IRBC), noticeably in relation to the
trophozoite count and schizont:trophozoite ratio 0.25:1. On intravenous artesunate, the patient
deteriorated clinically in the first 24 hours. The trophozoite count increased from 1.2% IRBC at
baseline to 20.5% IRBC 18 hours following the start of treatment. By day three, the patient
recovered and was discharged on day seven having completed a seven-day treatment with
artesunate and mefloquine.
Conclusion: The malaria blood smear provides only a guide to the overall parasite biomass in the
body, due to the ability of P. falciparum to sequester in the microvasculature. In severe malaria, high
schizont counts are associated with worse prognosis. In low transmission areas or in non-immune
travelers the presence of schizonts in the peripheral circulation is an indication for close patient
supervision. In this case, an unusually high schizont count in a clinically uncomplicated patient was
indicative of potential deterioration. Prompt treatment with intravenous artesunate is likely to have
been responsible for the good clinical outcome in this case.
Background
The 2006 WHO malaria treatment guidelines [1] laid out
in a user friendly volume give treatment recommenda-
tions based on the available evidence. The severity of
malaria, and hence treatment options, are determined
from the clinical features of a patient and supported by
the laboratory detection of parasites in the blood. There is
a variable relationship between parasite density and dis-
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higher the parasite count, the more severe the infection.
However, this is not a linear relationship. High parasite
counts can be found in asymptomatic individuals [3],
while some others can die of cerebral malaria with no par-
asites detected in the peripheral blood, although this is
rare and was only observed in the largest series of cerebral
malaria autopsies following effective antimalarial treat-
ment [4]. On the Thai-Burmese border, patients with
more than 4% IRBC, but no clinical signs of severe infec-
tion had a case fatality rate of 3% compared to an overall
case fatality of 1.9 per 1000 for malaria [5] i.e. 15 times
higher. Beside the absolute parasite density, the presence
of schizonts on the blood film and pigment in the neu-
trophils are good indicators of more severe infection and
warrant the clinician's attention as these patients may rap-
idly deteriorate. The following case demonstrates another
of the vagaries of malaria diagnosis, which presented a
management dilemma beyond the scope of the current
WHO malaria treatment guidelines.
Case presentation
A 28 year old male from the eastern border of Burma
walked to a malaria clinic on the Thai side of the river that
marks much of the border between the two countries. He
complained of a three-day history of fever, nausea, head-
ache and dizziness. He denied ever having had malaria in
the past. He was fully conscious, able to answer all ques-
tions appropriately and had an aural temperature of
37.5°C, pulse 88 beats/min, respiratory rate 20/min and
blood pressure 110/60 mmHg. His liver could just be pal-
pated, 1 cm below the costal margin in the mid-clavicular
line and his spleen was not palpable. Examination was
otherwise unremarkable. In particular, he had no signs
suggestive of severe malaria [6].
At the outpatient department, a rapid diagnostic test
(Paracheck®Pf) result was strongly positive and, conse-
quently, a malaria blood smear was taken. The malaria
smear result (12:20 hrs) was Plasmodium falciparum tro-
phozoites 12/1,000 RBC (equivalent to a parasitaemia of
51,245/µL (or 1.2% IRBC). Plasmodium falciparum sch-
izonts were present on the slide and the count was high:
3/1,000 RBC (equivalent to a schizontaemia of 12,811/µL
or 0.3% IRBC). Plasmodium vivax trophozoites were also
noted at low density: 8/500 White Blood Cells (WBC) (or
a parasitaemia of 128/µL). Scarce malaria pigment was
observed in < 1% of polymorphonuclear leucocytes (neu-
trophils) (Figure 1). On admission his capillary blood
haematocrit (HCT) was 34% and blood glucose 102 mg/
dL.
The patient exhibited no signs of severe malaria but was
admitted to hospital and treated according to the WHO
severe malaria protocol [1] on the basis of the high sch-
izont count (Table 1) and the presence of pigment. He
received a 5% dextrose infusion with 2.4 mg/kg IV artesu-
nate (currently the most potent antimalarial) at 0, 12 and
24 hrs, then every 24 hours for a total of five doses. The
available blood smear results during this patient's entire
admission have been summarized (Table 1). The tropho-
zoite parasitaemia increased from 1.2% to 20.5% in
approximately 18 hours (Table 1). In the first 24 hours,
the clinical condition of the patient deteriorated as he
developed hyperpyrexia (temperature 40°C), associated
with worsening headache and recurrent vomiting. His
urine was blood-stained, but this had resolved by the 2nd
day of treatment. His urine output was monitored, as was
blood glucose (6-hourly), and these were all just within
normal limits. The patient felt very well on the 3rd day of
treatment but did have a spontaneous nose bleed on this
day. The treatment was changed to oral artesunate and
mefloquine (15 mg/kg on the 6th day and 10 mg/kg on the
7th day of treatment). Fever clearance time was 66 hours
and time to parasite clearance (based on 24 hourly blood
smears) was 144 hours. This patient had a negative thalas-
saemia screen, mild anaemia and thrombocytopaenia, by
complete blood count (taken on the 4th day of treatment):
white blood cell 8.9 × 103/µL, haemoglobin 11.2 g/dL and
platelet count 125 × 103/µL,
Conclusion
This man had a presenting falciparum trophozoite parasi-
taemia of 51,245/µL and a very high schizont parasitae-
mia of 15,072/µl (Table 2) (total 67,117/µl) with no
clinical signs that would guide the physician towards clas-
sifying this patient as having severe malaria [3]. His para-
sitaemia was well below the WHO Malaria Treatment
Guidelines 2006 cut-off for hyperparasitaemia (4% IRBC
in a low transmission area ≈150,000/µL) and the concen-
tration of pigment containing neutrophils (<1%) was also
well below the 5% or greater concentration that has been
associated with a poor prognosis [7]. The only sentence in
the guidelines which might alert the physician to the
potential seriousness of this case was: "At any parasitae-
mia, prognosis worsens if there is a predominance of
more mature parasite stages [1]."
Table 2 summarizes schizont count results and schizont:
trophozoite ratio from patients from the same popula-
tion, with acute uncomplicated falciparum malaria on the
Thai-Burmese border, or with severe malaria from SE Asia.
This patient had a schizont count in the same range as has
been more commonly reported from patients presenting
with hyperparasitaemic and severe malaria and a high
ratio of schizonts to trophozoites. This case is a reminder
to consider all the details of a malaria smear when decid-
ing on treatment. The physician on duty was alerted by the
malaria smear result despite the fact the patient was clini-
cally uncomplicated. The trophozoite and schizont countPage 2 of 5
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malaria treatment was probably very wise considering the
early clinical deterioration.
High parasite densities are frequently equated with severe
disease but the reverse is not always true. There may be
wide differences between the number of parasitized cells
in the peripheral blood smear and the number seques-
tered in the microvasculature[3,8]. This case was unusual
because it is the mature stages that are normally seques-
tered and as a result not picked up by peripheral blood
microscopy. It is logical that a high schizont count should
be considered a danger sign – one P. falciparum schizont
releases an average of 16 merozoites, each of which can
theoretically infect another RBC causing the infective bio-
mass to expand exponentially. Modelling data of real
patients with acute uncomplicated falciparum malaria,
White and co-workers [9] demonstrated that during the
rising phase of the infection the ratio of circulating to
sequestered parasites was more dependent on synchronic-
ity of infection than multiplication rate. As well, when the
mean stage of parasite development is in the second half
of the asexual life cycle, synchronous infections showed
considerable fluctuations.
Although antimalarials are frequently referred to as blood
schizontocides, in fact mature trophozoites are more sus-
ceptible to the drugs and formed schizonts are relatively
drug- resistant [10]. Young ring trophozoites are also rela-
tively drug resistant (particularly to quinine and
Thick blood film of patient on admission demonstrating significant presence of schizonts compared with trophozoites (oil immersi n × 1000)Figure 1
Thick blood film of patient on admission demonstrating significant presence of schizonts compared with tro-
phozoites (oil immersion × 1000).
Table 1: Summary of malaria blood smear results, haematocrit and P. falciparum parasitaemia, until malaria smear negative.








Malaria pigment in 
neutrophils
HCT%
H 0 12/1000 RBC 51,245 3/1000 RBC 8/500 WBC < 1% 34
H 18 205/1000 RBC 725,340 9/500 WBC Neg 2+ 34
H 42 88/1000 RBC 338,492 Neg Neg 1+ -
H 66 10/500 WBC 178 Neg Neg 1+ -
H 90 2/500 WBC 36 Neg Neg Neg -
H 114 neg - Neg Neg Neg -Page 3 of 5
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large ring-form and mature trophozoite parasite stages.
The main stage targeted by quinine is the mature tropho-
zoite while the antifols act a little later [11]. The artemisi-
nin derivatives have the broadest time window of
antimalarial effect (from ring forms to early schizonts).
These compounds prevent maturation of ring stages, thus
reducing subsequent cytoadherence responsible for severe
disease [12]. Hence an artemisinin derivative was the drug
of choice in this case and the parenteral route ensured
adequate drug levels were reached quickly.
This report comes from an area of low transmission. In
areas of low transmission where immunity remains poor
across all age groups, or in returned travelers, even a low
schizont count is an indicator for close patient observa-
tion. The advantages of access to high quality microscopy
with parasite staging are shown here but would be consid-
ered a luxury in many malaria endemic settings [13],
where accurate parasite identification and quantification
may not be possible. Increasing reliance on rapid diagnos-
tic tests is likely to increase accuracy of malaria diagnosis
overall but certain information can only be provided by
slide microscopy.
When treating P. falciparum malaria one needs to account
for all stages reported from the malaria blood smear bear-
ing in mind it provides only a guide to the total parasite
biomass. Any clinical deterioration in a patient on oral
treatment necessitates a change to the severe malaria pro-
tocol. High parasite counts, as anticipated in this patient,
are best treated with artemisinin derivatives.
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